Seong-Jang Kim1, Samuel Chang. 1. Department of Nuclear Medicine, Pusan National University Hospital, Busan, Republic of Korea.
Abstract
BACKGROUND: The purpose of this study was to evaluate the prognostic value of the maximum standard uptake value (SUV max) measured by 18-F fluoro-2-deoxy-d-glucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) in newly diagnosed small cell lung cancer (SCLC) patients. METHODS: We reviewed the medical records of newly diagnosed SCLC patients who were given a histological diagnosis from June 2008 to June 2014. 82 patients who satisfied the inclusion criteria were enrolled for final analysis (male n = 75, female n = 7). The relationship between SUV max and overall survival (OS) and progression-free survival (PFS) was evaluated. RESULTS: Median follow-up was 25.0 months (range 11.6-55.5 months). The median OS was 11.2 months (range 1.6-55.5 months), and the median PFS was 6.1 months (range 0.9-55.5 months). Survival analysis showed no statistical differences in OS and PFS between high and low SUV max groups. CONCLUSION: This study does not support the use of SUV max of pretreatment F-18 FDG PET/CT scans as a prognostic tool for patients with SCLC.
BACKGROUND: The purpose of this study was to evaluate the prognostic value of the maximum standard uptake value (SUV max) measured by 18-F fluoro-2-deoxy-d-glucose (F-18FDG) positron emission tomography/computed tomography (PET/CT) in newly diagnosed small cell lung cancer (SCLC) patients. METHODS: We reviewed the medical records of newly diagnosed SCLCpatients who were given a histological diagnosis from June 2008 to June 2014. 82 patients who satisfied the inclusion criteria were enrolled for final analysis (male n = 75, female n = 7). The relationship between SUV max and overall survival (OS) and progression-free survival (PFS) was evaluated. RESULTS: Median follow-up was 25.0 months (range 11.6-55.5 months). The median OS was 11.2 months (range 1.6-55.5 months), and the median PFS was 6.1 months (range 0.9-55.5 months). Survival analysis showed no statistical differences in OS and PFS between high and low SUV max groups. CONCLUSION: This study does not support the use of SUV max of pretreatment F-18FDG PET/CT scans as a prognostic tool for patients with SCLC.
Authors: Sara Lázaro; Miriam Pérez-Crespo; Corina Lorz; Alejandra Bernardini; Marta Oteo; Ana Belén Enguita; Eduardo Romero; Pilar Hernández; Laura Tomás; Miguel Ángel Morcillo; Jesús M Paramio; Mirentxu Santos Journal: Proc Natl Acad Sci U S A Date: 2019-10-14 Impact factor: 11.205